NYSE - ChemoCentryx, Inc.

График котировок ChemoCentryx, Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 66.52
P/BV 11.58
EV/EBITDA -104.03
EBITDA -0.0412
Цена ао 67.84

Все параметры ⇨

Оценка

Недооценка

Название Значение Оценка
P/S 66.52 1
P/BV 11.58 1
P/E 0
EV/EBITDA -104.03 10

Эффективность

Название Значение Оценка
ROA, % -7 1
ROE, % -17.57 1

Дивиденды

Название Значение Оценка
Div yield, % 0
DSI 0 0

Долг

Название Значение Оценка
Долг/EBITDA 0

Импульс роста

Название Значение Оценка
Рост прибыли, % 0 0
Рост цены акции, % 0 0
Рост дивидендов, % 0 0

Основные владельцы

Institutions Объем Доля, %
Hartford Funds Management Company, LLC 8153493 11.78
Peroni Portfolio Advisors, Inc 200 0
RA Capital Management, LLC 4826910 6.97
Opaleye Management Inc 356000 0.51
Hennion & Walsh, Inc 100 0
Integral Health Asset Management, LLC 185000 0.27
Cormorant Asset Management, LLC 1400000 2.02
SV Life Sciences Managers LLP 191600 0.28
Wells Fargo Funds Management LLC 381197 0.55
BlackRock Fund Advisors 4454590 6.44
Fidelity SelectCo, LLC 5212989 7.53
Knott David M 75033 0.11
Carmignac Gestion Luxembourg S.A. 58396 0.08
Crow Point Partners, LLC 1990 0
Prudential Retirement Services 123117 0.18
Fidelity Management & Research Company LLC 9783121 14.14
Mangrove Partners 353219 0.51
Northern Trust Investments Inc 942330 1.36
Morningstar 1337621 1.93
Mason Street Advisors, LLC 534954 0.77
Hennion & Walsh, Inc 100 0
Blue Rock Advisors Inc 53784 0.08
Fidelity Management & Research Company LLC 5351027 7.73
Allianz Global Investors GmbH 76692 0.11
Invesco Capital Management LLC 483056 0.7
The Variable Annuity Life Insurance Company 142011 0.21
TimesSquare Capital Management, LLC 25370 0.04

Содержится в ETF

ETF Доля, % Доходность за год, % Дивиденды, %
ALPS Medical Breakthroughs ETF 3.03 34.21 0.50
Invesco DWA Healthcare Momentum ETF 2.68 63.70 0.60
iShares U.S. Pharmaceuticals ETF 1.24 21.89 1.20

Похожие компании

Описание ChemoCentryx, Inc.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.